<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">655536</article-id><article-id pub-id-type="doi">10.17816/KMJ655536</article-id><article-id pub-id-type="edn">IJZOQU</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Theoretical and clinical medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Теоретическая и клиническая медицина</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Ischemic heart disease after SARS-CoV-2 infection: a cross-sectional study</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности течения ишемической болезни сердца в постковидном периоде: одномоментное исследование</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>后腔期冠心病病程特点：单期研究</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4735-5178</contrib-id><contrib-id contrib-id-type="spin">5730-7589</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakhontov</surname><given-names>Davyd A.</given-names></name><name xml:lang="ru"><surname>Яхонтов</surname><given-names>Давыд Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, каф. фармакологии, клинической фармакологии и доказательной медицины</p></bio><email>mich99@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5097-1855</contrib-id><contrib-id contrib-id-type="spin">9797-7729</contrib-id><name-alternatives><name xml:lang="en"><surname>Derisheva</surname><given-names>Daria A.</given-names></name><name xml:lang="ru"><surname>Деришева</surname><given-names>Дарья Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент, каф. фармакологии, клинической фармакологии и доказательной медицины</p></bio><email>one.d@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1250-8798</contrib-id><contrib-id contrib-id-type="spin">7932-6544</contrib-id><name-alternatives><name xml:lang="en"><surname>Khidirova</surname><given-names>Lyudmila D.</given-names></name><name xml:lang="ru"><surname>Хидирова</surname><given-names>Людмила Даудовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, каф. фармакологии, клинической фармакологии и доказательной медицины</p></bio><email>h_ludmila73@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3411-508X</contrib-id><contrib-id contrib-id-type="spin">3950-3322</contrib-id><name-alternatives><name xml:lang="en"><surname>Lukinov</surname><given-names>Vitaly L.</given-names></name><name xml:lang="ru"><surname>Лукинов</surname><given-names>Виталий Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Physics and Mathematics), Leading research associate, Lab. of Numerical Analysis of Stochastic Differential Equations</p></bio><bio xml:lang="ru"><p>канд. физ.-мат. наук, ведущий научный сотрудник, лаб. численного анализа стохастических дифференциальных уравнений</p></bio><email>vitaliy.lukinov@sscc.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch RAS</institution></aff><aff><institution xml:lang="ru">Институт вычислительной математики и математической геофизики Сибирского отделения Российской академии наук</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-09-21" publication-format="electronic"><day>21</day><month>09</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-10-05" publication-format="electronic"><day>05</day><month>10</month><year>2025</year></pub-date><volume>106</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>707</fpage><lpage>716</lpage><history><date date-type="received" iso-8601-date="2025-02-13"><day>13</day><month>02</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-06-03"><day>03</day><month>06</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2025,</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-10-05"/></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/655536">https://kazanmedjournal.ru/kazanmedj/article/view/655536</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold>: The incidence of newly diagnosed stable angina after a SARS-CoV-2 infection remains high. However, studies on the clinical, functional, and laboratory characteristics of this disease are inadequate. The manifestations of ischemic heart disease (IHD) following SARS-CoV-2 infection require further investigation to elucidate the pathophysiological mechanisms and personalize follow-up care.</p> <p><bold>AIM</bold>: This study aimed to compare the clinical, functional, laboratory, and angiographic characteristics of stable angina in patients diagnosed with IHD following SARS-CoV-2 infection.</p> <p><bold>METHODS</bold>: This cross-sectional study assessed patients’ medical histories, along with clinical, laboratory, and instrumental findings. The study enrolled 428 patients with stable IHD and documented SARS-CoV-2 infection (within 3–18 months of the onset of the disease). Group 1 (<italic>n</italic> = 195) consisted of patients with newly diagnosed IHD, and group 2 (<italic>n</italic> = 233) included patients with previously diagnosed IHD, with the infection being documented to have occurred ≥12 weeks prior to study enrollment. IHD was diagnosed through a comprehensive evaluation that included clinical presentation, electrocardiographic analysis, echocardiographic imaging, stress tests, and coronary angiography. Blood chemistry was performed using standardized methods. Statistical analysis was carried out in RStudio. Continuous variables were compared using the Mann–Whitney <italic>U </italic>test, whereas the comparison of binary and categorical variables was conducted using Fisher’s exact test. The critical significance level was set at <italic>p</italic> = 0.05.</p> <p><bold>RESULTS</bold>: Group 1 was significantly younger (<italic>p</italic> = 0.009), had a lower body mass index (<italic>p</italic> &lt; 0.001), and had a shorter history of hypertension (<italic>p</italic> &lt; 0.001). These patients exhibited higher prevalence of functional class I angina pectoris (<italic>p</italic> = 0.006), NYHA class II chronic heart failure (<italic>p</italic> = 0.005), and lower prevalence of ventricular extrasystole (<italic>p</italic> = 0.002). Coronary angiography demonstrated that group 1 showed higher prevalence of unchanged coronary arteries (<italic>p</italic> = 0.003) and hemodynamically insignificant stenoses (<italic>p</italic> = 0.018), but lower proportion of hemodynamically significant stenoses (<italic>p</italic> &lt; 0.001). There were no significant differences found in the occurrence of multifocal atherosclerosis (<italic>p</italic> = 0.132). The treadmill test revealed comparable positive results across both groups (<italic>p</italic> = 0.479). However, group 1 exhibited a higher frequency of inconclusive results (<italic>p</italic> = 0.011). The laboratory profile of patients from group 2 showed increased Lp(a) (<italic>p</italic> = 0.023), triglycerides (<italic>p</italic> = 0.003), apoB (<italic>p</italic> = 0.022), NT-proBNP (<italic>p</italic> = 0.010), D-dimer (<italic>p</italic> = 0.001), high sensitivity C-reactive protein (<italic>p</italic> = 0.012), and cystatin C (<italic>p</italic> = 0.001), as well as higher fasting glucose (<italic>p</italic> = 0.030), but comparable HbA1c levels (<italic>p</italic> = 0.750).</p> <p><bold>CONCLUSION</bold>: Patients who develop stable angina following SARS-CoV-2 infection demonstrate a less severe clinical and functional phenotype, less significant coronary atherosclerosis, and more favorable biomarker profile than those with previously diagnosed IHD who had SARS-CoV-2 infection.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold>. Число случаев впервые диагностированной стабильной стенокардии в постковидном периоде остаётся высоким, однако клинико-функциональные и лабораторные характеристики этой группы пациентов изучены недостаточно. Исследование особенностей манифестации ишемической болезни сердца (ИБС) в постковидном периоде важно для понимания патофизиологических механизмов и персонализации последующего наблюдения.</p> <p><bold>Цель исследования</bold>. Сравнить клинико-функциональные, лабораторные и ангиографические характеристики стабильной стенокардии у пациентов с впервые диагностированной ИБС в постковидном периоде.</p> <p><bold>Методы</bold>.<bold> </bold>Выполнено одномоментное исследование с оценкой анамнеза, клинических, лабораторных и инструментальных данных. В исследование включены 428 пациентов со стабильной ИБС и документированной SARS-CoV-2-инфекцией (3–18 мес после заболевания). Сформированы две группы: 1-я (n=195) — впервые выявленная ИБС; 2-я (n=233) — ранее установленная ИБС, при этом инфекция была перенесена ≥12 нед до включения. Диагностика ИБС основывалась на клинической картине, электрокардиографии, эхокардиографии, нагрузочных тестах и коронароангиографии. Биохимические исследования образцов крови проведены по стандартизированным методикам. Статистический анализ выполняли в RStudio: непрерывные показатели сравнивали с использованием U-критерия Манна–Уитни, бинарные и категориальные — точным критерием Фишера; критический уровень значимости <italic>p</italic>=0,05.</p> <p><bold>Результаты</bold>. Пациенты 1-й группы были статистически значимо моложе (<italic>p</italic>=0,009), имели меньший индекс массы тела (<italic>p</italic> &lt;0,001) и более короткий анамнез артериальной гипертензии (<italic>p</italic> &lt;0,001). У них чаще наблюдалась стенокардия I функционального класса (<italic>p</italic>=0,006), хроническая сердечная недостаточность II класса по NYHA (<italic>p</italic>=0,005), а желудочковая экстрасистолия регистрировалась реже (<italic>p</italic>=0,002). По данным коронароангиографии в 1-й группе чаще выявлялись неизменённые коронарные артерии (<italic>p</italic>=0,003) и гемодинамически незначимые стенозы (<italic>p</italic>=0,018), при этом доля гемодинамически значимых стенозов была ниже (<italic>p</italic> &lt;0,001). Статистически значимых различий по частоте мультифокального атеросклероза не установлено (<italic>p</italic>=0,132). По результатам тредмил-теста частота положительных проб была сопоставима (<italic>p</italic>=0,479), однако сомнительные результаты чаще регистрировались в 1-й группе (<italic>p</italic>=0,011). В лабораторном профиле у пациентов 2-й группы наблюдались более высокие уровни Лп(а) (<italic>p</italic>=0,023), триглицеридов (<italic>p</italic>=0,003), ApoB (<italic>p</italic>=0,022), NT-proBNP (<italic>p</italic>=0,010), D-димера (<italic>p</italic>=0,001), высокочувствительного С-реактивного белка (<italic>p</italic>=0,012) и цистатина C (<italic>p</italic>=0,001). Также у них была выше глюкоза натощак (<italic>p</italic>=0,030), тогда как HbA1c не различался (<italic>p</italic>=0,750).</p> <p><bold>Заключение</bold>. Стабильная стенокардия, впервые диагностированная в постковидном периоде, ассоциируется с менее отягощённым клинико-функциональным фенотипом, менее выраженным коронарным атеросклерозом и более благоприятным биомаркерным профилем по сравнению с пациентами с ранее установленной ИБС, перенёсшими SARS-CoV-2-инфекцию.</p></trans-abstract><trans-abstract xml:lang="zh"><p><bold>论证：</bold>新诊断的后COVID时期稳定型心绞痛病例数仍然很高，但该组患者的临床，功能和实验室特征尚未得到充分研究。研究冠心病（CHD）在后COVID时期表现的特征对于理解随访的病理生理机制和个性化具有重要意义。</p> <p><bold>目的：</bold>比较新诊断冠状动脉疾病患者在COVID后期稳定型心绞痛的临床，功能，实验室和血管造影特征。方法：进行了一项单阶段研究，评估了病史，临床，实验室和仪器数据。该研究包括428名患有稳定冠心病的患者，并记录了SARS-CoV-2感染（疾病发生后3-18个月）。形成两组：1st（<italic>n</italic>=195）— 新诊断的冠心病；2nd（<italic>n</italic>=233）— 先前诊断的冠心病，而感染在纳入前≥12周传播。冠状动脉疾病的诊断基于临床图片，心电图，超声心动图，压力测试和冠状动脉血管造影。根据标准化方法进行血液样品的生物化学研究。在RStudio中进行统计分析：使用曼-惠特尼 U–检验比较连续指标，使用费舍尔精确准则比较二元和分类指标；临界显着性水平为<italic>p</italic>=0.05。</p> <p><bold>结果：</bold>第1组患者在统计学上显着年轻（<italic>p</italic>=0.009），体重指数较低（<italic>p</italic> &lt;0.001）和高血压病史较短（<italic>p</italic> &lt;0.001）。他们更可能患有功能性i类心绞痛（<italic>p</italic>=0.006），NYHA II类慢性心力衰竭（<italic>p</italic>=0.005），心室外壁不太常见（<italic>p</italic>=0.002）。根据冠状动脉造影数据，在第1组中更常检测到未改变的冠状动脉（<italic>p</italic>=0.003）和血流动力学显着性狭窄（<italic>p</italic>=0.018），而血流动力学显着性狭窄的比例较低（<italic>p</italic> &lt;0.001）。多灶性动脉粥样硬化的频率没有统计学上的显着差异（<italic>p</italic>=0.132）。根据跑步机测试的结果，阳性样本的频率相当（<italic>p</italic>=0.479），但在第1组中更经常记录可疑结果（<italic>p</italic>=0.011）。实验室检查结果显示，第2组患者的Lp（a）（<italic>p</italic>=0.023）、甘油三酯（<italic>p</italic>=0.003）、ApoB（<italic>p</italic>=0.022）、NT-proBNP（<italic>p</italic>=0.010）、D-二聚体（<italic>p</italic>=0.001）、高敏C反应蛋白（<italic>p</italic>=0.012）和胱抑素C（<italic>p</italic>=0.001）水平较高。他们的空腹血糖水平也较高（<italic>p</italic>=0.030），而HbA1c水平无显著差异（<italic>p</italic>=0.750）。</p> <p><bold>结论：</bold>稳定型心绞痛，首次诊断后COVID时期，是与负担较轻的临床和功能表型，不太明显的冠状动脉动脉粥样硬化，和更有利的生物标志物配置文件与以前诊断冠状动脉疾病</p></trans-abstract><kwd-group xml:lang="en"><kwd>ischemic heart disease</kwd><kwd>SARS-CoV-2 infection</kwd><kwd>COVID-19</kwd><kwd>stable angina</kwd><kwd>coronary angiography</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ишемическая болезнь сердца</kwd><kwd>инфекция SARS-CoV-2</kwd><kwd>постковидный период</kwd><kwd>COVID-19</kwd><kwd>стабильная стенокардия</kwd><kwd>коронароангиография</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>冠心病</kwd><kwd>SARS-CoV-2感染</kwd><kwd>COVID后期</kwd><kwd>COVID-19</kwd><kwd>稳定型心绞痛</kwd><kwd>冠状动脉造影</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Soriano JB, Murthy S, Marshall JC, et al; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–e107. doi: 10.1016/S1473-3099(21)00703-9 EDN: NHYDEH</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. doi: 10.1016/j.eclinm.2022.101762 EDN: KUBUIW</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Idris Fadul AA, Osman Mohamed AA, Mohammed Ahmed AAS, et al. Post-coronavirus Disease 2019 (COVID-19) Cardiovascular Manifestations: A Systematic Review of Long-Term Risks and Outcomes. Cureus. 2025;17(4):e83083. doi: 10.7759/cureus.83083.;PMCID</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–590. doi: 10.1038/s41591-022-01689-3 EDN: GXZXAU</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Rajan S, Hunt K, Alwan NA, et al. In the wake of the pandemic: Preparing for Long COVID [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK569598</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zhang T, Li Z, Mei Q, et al. Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12:1450470. doi: 10.3389/fcvm.2025.1450470.;PMCID</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Avanoglu Guler A, Tombul N, Aysert Yıldız P, et al. The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. Scand J Clin Lab Invest. 2021;81(2):160–165. doi: 10.1080/00365513.2021.1871641 EDN: DOHBWO</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Adu-Amankwaah J, Mprah R, Adekunle AO, et al. The cardiovascular aspect of COVID-19. Ann Med. 2021;53(1):227–236. doi: 10.1080/07853890.2020.1861644 EDN: AKMTRW</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Majure DT, Gruberg L, Saba SG, et al; Northwell Health COVID-19 Research Consortium. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury. Am J Cardiol. 2021;138:100–106. doi: 10.1016/j.amjcard.2020.09.060.;PMCID EDN: OMCZHY</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Canzano P, Brambilla M, Porro B, Cosentino N. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci. 2021;6(3):202–218. doi: 10.1016/j.jacbts.2020.12.009.;PMCID EDN: MJMJOJ</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Writing Committee; Gluckman TJ, Bhave NM, Allen LA, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717–1756. doi: 10.1016/j.jacc.2022.02.003 EDN: CZLRKH</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Gyöngyösi M, Alcaide P, Asselbergs FW, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc Res. 2023;119(2):336–356. doi: 10.1093/cvr/cvac115 EDN: RTNTNO</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Tsampasian V, Bäck M, Bernardi M, et al. Cardiovascular disease as part of Long COVID: a systematic review. Eur J Prev Cardiol. 2025;32(6):485–498. doi: 10.1093/eurjpc/zwae070 EDN: QLXRCO</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619 EDN: EVNIFG</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Çınar T, Şaylık F, Akbulut T, et al. One-year outcomes of invasively managed acute coronary syndrome patients with COVID-19. Heart Lung. 2022;52:159–164. doi: 10.1016/j.hrtlng.2022.01.012.;PMCID EDN: OZASIV</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Carnevale Schianca GP, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21:406–411. doi: 10.1016/j.numecd.2009.11.002</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305–368. doi: 10.1016/j.ejvs.2017.07.018 EDN: YDUSTB</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>van den Berg MJ, Bhatt DL, Kappelle LJ, et al. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. Eur Heart J. 2017;38(43):3211–3218. doi: 10.1093/eurheartj/ehx102 EDN: VFMEXY</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Grakova EV, Kopieva KV, Teplyakov AT, et al. Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test. Cardiovasc Ther Prev. 2019;18(4):12–18. doi: 10.15829/1728-8800-2019-4-12-18 EDN: IVHJZH</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up. Russian Journal of Cardiology. 2021;26(10):4708. doi: 10.15829/1560-4071-2021-4708</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhao M, Luo C, He H, Shen B, et al. Decreased low-density lipoprotein cholesterol level indicates poor prognosis of severe and critical COVID-19 patients: a retrospective, single-center study. Front Med. 2021;8:585851. doi: 10.3389/fmed.2021.585851 EDN: DOMYAS</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Kanorskii SG. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Sci Med Bull. 2021;28(6):90–116. (In Russ.) doi: 10.25207/1608-6228-2021-28-6-90 EDN: KZFQTW</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Gomes SMR, Brito ACS, Manfro WFP, et al. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. PLoS One. 2023;18(4):e0283983. doi: 10.1371/journal.pone.0283983.;PMCID EDN: EMFKXW</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Elizalde-Díaz JP, Miranda-Narváez CL, Martínez-Lazcano JC, Martínez-Martínez E. The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Front Immunol. 2022;13:1039427. doi: 10.3389/fimmu.2022.1039427 EDN: SILHPD</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tajmirriahi M, Sami R, Mansurian M, et al. Clinical manifestations and outcomes of COVID-19 in patients with a history of coronary artery disease: a case-control retrospective study. BMC Cardiovasc Disord. 2023;23:241. doi: 10.1186/s12872-023-03256-1 EDN: SEWVGF</mixed-citation></ref></ref-list></back></article>
